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 INTRODUCTION
 Irritable bowel syndrome (IBS) is a functional bowel disorder 
characterized by chronic or recurrent symptoms of abdominal 
pain that is associated with altered bowel function (i.e., pain 
related to defecation, changes in stool frequency, or appear-
ance) ( 1–3 ). Additional symptoms of IBS may include straining, 
fecal urgency, and bloating ( 1 ). IBS can further be subdivided by 
stool consistency, namely, constipation-predominant IBS (IBS-C), 
diarrhea-predominant IBS (IBS-D), or mixed bowel habit pattern 
(IBS-M). Importantly, patients with IBS report reduced health-
related quality of life (HRQOL) compared with individuals with-
out IBS ( 4 ).
 As many as 48 million individuals in the United States are 
thought to be aff ected by IBS annually ( 5 ), yet up to 75% of 
patients with IBS may lack a formal medical diagnosis of IBS ( 6 ). 
Although diagnostic symptom criteria exist for IBS ( 1,3 ), they are 
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IBS in Diagnosed Vs. Undiagnosed Individuals
mainly used in clinical research studies, rather than used routinely 
in clinical practice. In a US study using a large health insurance 
database, patients with IBS were most likely to receive a diagno-
sis from an internist (68%) rather than a gastroenterologist (13%) 
( 7 ). Hungin  et al. ( 8 ) conducted a European study that surveyed 
3,880 participants with IBS symptoms and suggested that primary 
care physicians may have an even greater role in IBS diagnosis and 
management; the authors found that most patients with medically 
diagnosed IBS sought medical care from primary care physicians 
(90%) rather than gastroenterologists (28%). Of symptomatic indi-
viduals lacking a medical diagnosis of IBS, Hungin  et al. ( 8 ) found, 
for a European population, that 37% did not receive care, whereas 
55 and 12% sought medical care from primary care physicians 
and gastroenterologists, respectively. A comparable, but smaller, 
US community survey study conducted by the same group found 
similar results ( 6 ). Th e reasons for the lack of a formal diagnosis of 
IBS for many individuals are not entirely clear, but likely are multi-
factorial. Individuals with IBS symptoms oft en describe a range of 
gastrointestinal (GI) symptoms, including refl ux-like symptoms, 
dyspepsia, and IBS-related symptoms (e.g., fecal urgency, bloating) 
( 9 ). IBS-D may pose a relatively greater diagnostic challenge than 
the other bowel habit subtypes, as celiac disease and infl ammatory 
bowel disease, among other conditions, need to be considered in 
patients with chronic or recurrent diarrhea ( 10 ). In fact, current 
evidence suggests that celiac serologies and infl ammatory markers 
such as C-reactive protein and fecal calprotectin should be 
obtained in these patients ( 11 ).
 Previous studies have compared GI and psychologic symptoms 
between individuals with IBS symptoms who seek healthcare and 
those who do not; however, diff erences between individuals with 
diagnosed and undiagnosed IBS (including those who had visited 
a physician for their IBS-related symptoms) have not been well 
studied. Th e European and US surveys performed by Hungin  et al. 
( 6,8 ) were conducted >10 years ago, used older diagnostic criteria 
for IBS and bowel habit subtypes, and did not focus on patients 
with IBS-D.
 Th us, the objective of this investigation was to compare symp-
tom characteristics, healthcare utilization, HRQOL, treatments, 
and perceived explanations for GI symptoms in patients diagnosed 
with IBS-D using contemporary criteria compared with individu-
als who remain undiagnosed despite having sought medical atten-
tion for IBS-related symptoms.
 METHODS
 Study participants
 Individuals ≥18 years of age from a general US population sam-
ple who had previously responded to invitations to participate 
in various surveys for two diff erent fi rms and who indicated in 
a profi le questionnaire that they had experienced GI issues were 
eligible for inclusion in the survey. An invitation to complete an 
online survey was sent by e-mail to eligible individuals in the two 
databases, with up to three additional e-mail reminders sent to 
nonresponders. Th e survey was conducted between 1 September 
2014 and 15 September 2014, and assessed the frequency and 
severity of GI symptoms, number and type of healthcare visits, 
general well-being, management of symptoms, and treatment 
satisfaction. A point system redeemable for various rewards (e.g., 
gift  cards) was used as an incentive for participation in the survey.
 Participants were classifi ed as patients with diagnosed IBS if 
they indicated that a healthcare provider had diagnosed them as 
having IBS (i.e., “diagnosed patients”). Participants were classifi ed 
as individuals with undiagnosed IBS-D (i.e., “undiagnosed indi-
viduals”) if their symptoms were compatible with IBS according 
to Rome III criteria ( 1 ) based on their survey responses, but they 
had not received a medical diagnosis of IBS. Hence, undiagnosed 
individuals with IBS-D symptoms reported abdominal pain and 
discomfort at least 2 to 3 days per month for at least the previ-
ous 3 months. Furthermore, these symptoms were accompanied 
by more frequent bowel movements and looser stools, and indi-
viduals experienced improvement in abdominal pain or dis-
comfort with a bowel movement. Individuals were not included 
in the study if they reported constipation as “always” occurring or 
if their associated stomach issues were predominantly accompa-
nied by constipation. Individuals were also not included in the 
analysis if they reported having irregular hematochezia or ano-
rectal bleeding in the previous month or if they had previous 
GI surgery.
 Assessments
 Symptom severity was scored on a 7-point scale (range: 1=very 
mild to 7=very severe). Disruptiveness of symptoms was also 
scored on a 7-point scale (range: 1=not at all disruptive to 
7=extremely disruptive), as was satisfaction with current treat-
ments (range: 1=extremely unsatisfi ed to 7=extremely satisfi ed). 
Adjustments to daily living invoked to control symptoms were 
determined based on 11 predefi ned responses, or a choice of 
“other” or “none of the above” to the question: “Which, if any, of 
the following things do you do in your day-to-day life in order 
to manage your (IBS/stomach problems)?” Detailed information 
regarding questions and response options are included in  Table 1 
in the  Supplementary Information online.
 Statistically signifi cant diff erences between diagnosed and undi-
agnosed populations were calculated using a  z -test for proportions 
and only calculated as  P <0.05, which was considered statistically 
signifi cant, or  P ≥0.05, which was considered not statistically sig-
nifi cant.
 Role of the sponsor
 Th e study was sponsored by Salix Pharmaceuticals, which had a 
role in study design and data analysis.
 RESULTS
 Study participants
 A total of 126,057 individuals pooled from 2 separate groups 
of potential respondents were sent an invitation by e-mail to 
participate in the survey. Of the 23,707 individuals (18.8%) 
who accessed the link to the survey, 1,924 (1.5%) completed the 
survey, thus meeting the eligibility criteria for inclusion in the 
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study ( Supplementary Figure S1 online). Of these individuals, 
1,094 (56.9%) met the criteria for an IBS-D diagnosis; despite 
meeting the Rome III criteria for IBS-D, 830 individuals (43.1%) 
had not received a medical diagnosis of IBS. In the undiagnosed 
group, 53% of individuals reported that they had never spoken 
with a physician regarding their stomach problems.
 Of the diagnosed patients, 45% and 42% of patients received a 
diagnosis from either a gastroenterologist or a primary care physi-
cian, respectively. Internists diagnosed 11% of patients with IBS-D. 
Compared with undiagnosed individuals, diagnosed patients were 
more commonly white and female ( P <0.05;  Table 1 ). Older indi-
viduals (≥60 years of age) were also more likely to be diagnosed 
with IBS. Furthermore, diagnosed patients had consulted a greater 
number of physicians and had more GI consultations as compared 
with undiagnosed individuals ( P <0.05 for all comparisons), with the 
percentage of diagnosed and undiagnosed individuals consulting 
healthcare providers increasing with a longer duration of symptoms.
 GI symptom history and impact on HRQOL
 A signifi cantly greater percentage of diagnosed patients had GI 
symptoms for ≥10 years compared with undiagnosed individuals 
(55% vs. 18%, respectively;  P <0.05). Conversely, a signifi cantly 
greater percentage of undiagnosed individuals had symptoms for 
<3 years compared with diagnosed patients (51% vs. 14%, respec-
tively;  P <0.05). Diagnosed patients were twice as likely to have 
severe GI symptoms (i.e., severity score, 6 or 7) than undiagnosed 
individuals (16% vs. 8%, respectively;  P <0.05), whereas undi-
agnosed individuals were signifi cantly more likely to have mild 
symptoms (i.e., severity score, 1 or 2) compared with diagnosed 
patients (6% vs. 3%, respectively;  P <0.05). A greater percentage 
of diagnosed patients had more severe symptoms compared with 
individuals in the undiagnosed group for discomfort/pain (diag-
nosed, 36% vs. undiagnosed, 24%), diarrhea (52% vs. 29%), loose/
mushy stools (49% vs. 29%), urgency (61% vs. 41%), and bloating 
(26% vs. 20%);  P <0.05 for all comparisons ( Figure 1a ).
 Diagnosed patients had more disruptive IBS-associated symp-
toms than individuals in the undiagnosed group, including dis-
comfort/pain (32% vs. 27%), diarrhea (61% vs. 40%), loose/mushy 
stools (44% vs. 27%), and urgency (64% vs. 46%);  P <0.05 for all 
comparisons ( Figure 1b ). Bloating occurred in a comparable 
percentage of individuals (19% vs. 18%). Yet, undiagnosed indi-
viduals had more “confounder” symptoms (i.e., heartburn, gastric 
refl ux, constipation) than diagnosed patients. When experien-
cing GI symptoms of pain or discomfort and diarrhea, diagnosed 
patients reported IBS-associated symptoms (e.g., bowel move-
ment urgency, bloating, nausea) “always or most of the time” with 
greater frequency than undiagnosed individuals ( Figure 2 ).
 In addition, both diagnosed and undiagnosed patients 
reported that HRQOL was adversely impacted by GI symptoms 
( Supplementary Table S2 online). However, a signifi cantly greater 
percentage of diagnosed patients than undiagnosed individuals 
reported cancelling or changing plans at the last minute (52% vs. 
39%, respectively), premedicating with antidiarrheal agents (50% 
vs. 33%), and avoiding food consumption before important events 
(52% vs. 39%), events with poor bathroom access (e.g., outdoor 
activity; 42% vs. 27%), work activities (38% vs. 28%), or dinner or 
social events with friends (34% vs. 23%), because of symptoms of 
IBS ( P <0.05 for all comparisons).
 Management of GI symptoms
 Diagnosed patients reported using a greater mean number of 
treatments in the past compared with undiagnosed individuals 
(4.9 vs. 3.4, respectively), including in the past 3 months (2.6 vs. 
 Table 1 .  Population demographics and symptom history 
  Individuals,  N  (%) 
 
 Parameter 
 Diagnosed with 
IBS-D ( n =1,094) 
 Undiagnosed 
( n =830) 
 Male/female (%)  241:853 a (22:78 a )  299 b :531 (36 b :64) 
 Age range, years ( n , %) 
 18–39  416 (38)  332 (40) 
 40–59  437 (40)  398 (48) b 
 ≥60  241 (22) a  100 (12) 
 Race/ethnicity ( n , %) 
 White  1,017 (93) a  714 (86) 
 Black  33 (3)  50 (6) b 
 Hispanic/Latino  33 (3)  42 (5) 
 Asian-American/Asian  22 (2)  33 (4) b 
 Other ethnicity  11 (1)  25 (3) 
 Symptom duration, years ( n , %) 
 <5  272 (25)  546 (66) b 
 5–10  218 (20) a  134 (16) 
 ≥10  604 (55) a  150 (18) 
 Symptom intensity ( n , %) 
 Mild (score, 1–2)  33 (3)  50 (6) b 
 Moderate (score, 3–5)  886 (81)  714 (86) 
 Severe (score, 6–7)  175 (16) a  66 (8) 
 Consulted ≥3 physicians ( n , %) 
 Symptoms <5 years  60 (22) a , c  33 (6) d 
 Symptoms 5–10 years  83 (38) a , e  23 (17) f 
 Symptoms ≥10 years  302 (50) a , g  44 (29) h 
 Consultation with gastroenterologist ( n , %) 
 Symptoms <5 years  139 (51) a , c  137 (25) d 
 Symptoms 5–10 years  122 (56) a , e  40 (30) f 
 Symptoms ≥10 years  405 (67) a , g  68 (45) h 
 IBS-D, diarrhea-predominant irritable bowel syndrome. 
 a P <0.05 vs. undiagnosed. 
 b P <0.05 vs. diagnosed. 
 c n =272. 
 d n =546. 
 e n =218. 
 f n =134. 
 g n =604. 
 h n =150. 





















IBS in Diagnosed Vs. Undiagnosed Individuals
2.1, respectively;  Table 2 ). However, few individuals with either 
diagnosed or undiagnosed IBS reported satisfaction with treatment 
(20% vs. 18%, respectively). A signifi cantly greater percentage of 
diagnosed patients reported satisfaction with specifi c treatments 
than undiagnosed individuals, notably antidiarrheals (30% vs. 




























































 Figure 1 .  Severity and disruptiveness of bowel movement characteristics. Severity ( a ) was determined by a score of 6 or 7 on a 7-point scale (range: 
1=very mild to 7=very severe). Disruptiveness ( b ) was determined by a score of 6 or 7 on a 7-point scale (range: 1=not at all disruptive to 7=extremely 




























 Figure 2 .  Additional symptoms experienced “always or most of the time.”  a P <0.05 vs. undiagnosed group.
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with 39% and 34% of undiagnosed individuals, respectively 
( P <0.05 for both comparisons;  Figure 3 ). Furthermore, diag-
nosed patients were signifi cantly more likely than undiagnosed 
individuals to believe anxiety (45% vs. 31%, respectively), genetics 
(31% vs. 17%, respectively), and/or imbalances in the gut micro-
biota (“imbalance of bacteria within my stomach or gut”; 23% 
vs. 18%, respectively) caused IBS ( P <0.05 for all comparisons). 
Finally, 29% and 16% of diagnosed and undiagnosed participants, 
respectively, believed “this is just the way my body works” was a 
cause for IBS ( P <0.05).
 Almost half (47%) of undiagnosed individuals reported speak-
ing with their physician about stomach problems, with the major-
ity of these individuals speaking with 1 or 2 physicians (54% and 
33%, respectively). Most undiagnosed individuals had considered 
that they might have IBS (67%;  Supplementary Figure S2 online). 
However, 61% of undiagnosed individuals never considered they 
might have the IBS-D form of IBS. Another 20% of undiagnosed 
individuals reported that they had considered that they might have 
IBS-D, but had never asked their physician about it, and 19% of 
undiagnosed individuals reported speaking with their physician, 
who stated that they did not have IBS-D.
 P <0.05). Furthermore, diagnosed patients were signifi cantly more 
likely to have received antidepressants or psycho logic therapies 
compared with undiagnosed individuals (antidepressants, 29% 
vs. 16%, respectively; psychological therapies, 15% vs. 9%;  P <0.05 
for both comparisons). In addition, diagnosed patients were more 
likely to report adjustments to daily activities as a result of GI 
symptoms compared with undiagnosed individuals ( Table 3 ).
 Th e largest share of participants received treatment for their 
IBS symptoms from primary care physicians (41% of diagnosed 
patients and 38% of undiagnosed individuals). Of these, internists 
treated 8% and 6% of diagnosed and undiagnosed individuals for 
IBS symptoms, respectively ( P <0.05). A signifi cantly greater per-
centage of diagnosed patients received treatment from a gastroen-
terologist compared with undiagnosed individuals (23% vs. 9%, 
respectively;  P <0.05). In all, 26% of diagnosed patients and 43% of 
undiagnosed individuals were currently not receiving treatment 
for their IBS symptoms.
 Perceptions about etiology of IBS symptoms
 More than half of diagnosed patients believed that stress (54%) 
and sensitivities to specifi c foods (52%) caused IBS as compared 
 Table 2 .  Treatments administered to help manage symptoms of irritable bowel syndrome 
  Individuals,  N  (%) 
  Current treatments b  Past treatments 
 Treatment with recommendation score and quality of 
evidence (in brackets) a 
 Diagnosed with IBS-D 
( n =1,094) 
 Undiagnosed 
( n =830) 
 Diagnosed with IBS-D 
( n =1,094) 
 Undiagnosed 
( n =830) 
 Level 2 recommendations 
 Antidepressants (2A)  175 (16) c  66 (8)  317 (29) c  133 (16) 
 Bulking agents or ﬁ ber supplements (2B)  219 (20) c  75 (9)  558 (51) c  216 (26) 
 Antibiotics (2B)  33 (3)  25 (3)  153 (14)  100 (12) 
 Alosetron (2B)  11 (1)  0 (0)  44 (4)  8 (1) 
 Antispasmodics (2C)  131 (12) c  17 (2)  328 (30) c  33 (4) 
 Probiotics (2C)  372 (34) c  199 (24)  689 (63) c  349 (42) 
 Dietary manipulation (2D)  459 (42) c  307 (37)  755 (69) c  481 (58) 
 Psychological therapies to reduce stress (2D)  66 (6) c  42 (5)  164 (15) c  75 (9) 
 Level 1 recommendation of insufﬁ cient evidence to recommend use 
 Antidiarrheals (1D)  394 (36) c  208 (25)  711 (65) c  382 (46) 
 No recommendation provided; not evaluated 
 OTC agents for upset stomach (NA)  306 (28)  324 (39) d  667 (61)  498 (60) 
 Lifestyle adjustments to reduce stress (NA)  252 (23) c  141 (17)  449 (41) c  232 (28) 
 Incorporation of more exercise into routine (NA)  186 (17) c  100 (12)  372 (34) c  183 (22) 
 Treatments, mean  2.6  2.1  4.9  3.4 
 IBS-D, diarrhea-predominant irritable bowel syndrome; NA, not applicable; OTC, over the counter. 
 a Scoring of recommendations and quality of evidence based on GRADE approach: 1=strong recommendation for or against use; 2=weak recommendation for or against 
use; A=high quality of evidence; B=moderate quality of evidence; C=low quality of evidence; D=very low quality of evidence. Recommendation and quality of evidence 
data from Ford  et al. ( 2 ). 
 b Used within the past 3 months. 
 c P <0.05 vs. undiagnosed. 
 d P <0.05 vs. diagnosed. 





















IBS in Diagnosed Vs. Undiagnosed Individuals
 Diagnosed and undiagnosed participants reported that their 
physicians had described a mean of 3.1 and 2.3 factors, respec-
tively, that may be contributing to their IBS/stomach problems. 
Only 15% of participants reported that they were provided only 
one cause of their IBS/stomach problems by physicians. Factors 
provided by physicians varied signifi cantly between diagnosed 
and undiagnosed participants and included stress or anxiety (67% 
vs. 37%, respectively;  P <0.05), specifi c food sensitivities (58% vs. 
32%,  P <0.05), gut microbiota imbalances (34% vs. 16%;  P <0.05), 
genetics (32% vs. 14%;  P <0.05), and “this is just the way my body 
works” (21% vs. 7%;  P <0.05).
 DISCUSSION
 In this study, we report on a cohort of internet survey respond-
ers who met Rome III criteria for IBS-D, comparing the clinical 
features of participants formally “diagnosed” with IBS-D with 
those of “undiagnosed” individuals similarly aff ected by IBS-D 
symptoms. Th e survey revealed that more than two in every fi ve 
individuals experiencing IBS-D symptoms had not been formally 
diagnosed with the condition.
 Although this undiagnosed group refl ects a substantial portion 
of individuals reporting IBS-like symptoms, a smaller US study 
by Hungin  et al. ( 6 ) previously reported that most individuals 
(>75%) meeting IBS diagnostic criteria had not been formally 
diagnosed by a physician with IBS (any subtype). However, only 
53% of those not medically diagnosed with IBS had visited a med-
ical professional at some point for their condition; this rate is in 
line with that observed in the current study. Although this study 
employed diff erent study methodologies and criteria to defi ne 
IBS, and limited its focus to diarrhea-predominant symptoms, we 
interpret this improvement in rates of IBS diagnosis to, in part, 
refl ect an enhanced awareness of IBS on behalf of patients and 
physicians alike. Earlier research has suggested that gastroenter-
ologists have reasonable familiarity with Rome diagnostic crite-
ria, whereas general practitioners may be less familiar with these 
criteria ( 12,13 ), and perhaps less comfortable in making an IBS 
diagnosis based on symptom-based criteria alone ( 14 ). Th is latter 
observation might continue to pose a challenge in establishing 
defi nitive IBS diagnoses, particularly in light of these data sug-
gesting that less than half of potential IBS diagnoses are made by 
gastroenterologists. Gastroenterologist consultation ultimately 
may be an important step in expediting IBS diagnoses; in those 
experiencing IBS-D symptoms for <5 years in this survey, gas-
troenterologist consultations were reported by IBS-D-diagnosed 
individuals at rates double those of undiagnosed participants 
(51% vs. 25%, respectively). It should be acknowledged that the 
IBS-D-diagnosed patients generally utilized more healthcare 
services, with higher rates of physician consultation (even when 
stratifi ed by duration of symptoms), and signifi cantly greater 
rates of GI/abdominal surgery. Th ese health-seeking behaviors 
of IBS-D-diagnosed patients alone may have facilitated physician 
diagnoses.
 Individuals diagnosed with IBS-D in this study reported more 
severe and disruptive symptoms, particularly abdominal pain and 
alterations in bowel frequency/consistency, and endorsed greater 
impact of their symptoms on HRQOL. Chronic symptoms with-
out revelation of an organic process should further facilitate an 
IBS diagnosis, and, indeed, more than half of IBS-diagnosed par-
ticipants in this survey reported having symptoms for >10 years; 
conversely, 51% of undiagnosed individuals reported symptoms 
of <3 years in duration. Undiagnosed individuals in this study 
reported proportionately greater numbers of GI symptoms not 
typically associated with IBS-D, such as heartburn/GI refl ux dis-
ease, that may have further confounded physicians’ abilities to 
confi dently diagnose IBS-D. Taken together, these data highlight 
the importance of maintaining a high index of suspicion in estab-
lishing a diagnosis of IBS, particularly in cases with milder symp-
toms of shorter durations, or in the context of less typical symptom 
presentations.
 Th e data suggest that formal IBS-D diagnoses may be impor-
tant for two reasons. First, an IBS diagnosis may facilitate the dia-
logue between the patient and physician about treatment options. 
Patients diagnosed with IBS-D were off ered more treatments 
and were found to have greater access to evidence-based, proven 
therapies. Indeed, a greater percentage of patients with diagnosed 
IBS received prescription treatment for symptoms compared 
with undiagnosed individuals with IBS symptoms (50% vs. 30%, 
 Table 3 .  Lifestyle modiﬁ cations used to manage symptoms of 
irritable bowel syndrome 
 Positive response to “Which, if any,   Individuals,  N  (%) 
 
 of the following things do you do in 
your day-to-day life in order to man-
age your (IBS/stomach problems)?”
 
 Diagnosed with 
IBS-D ( n =1,094) 
 Undiagnosed 
( n =830) 
 Avoid foods that I think will upset my 
stomach 
 799 (73) a  506 (61) 
 Always know where bathrooms are 
located 
 733 (67) a  407 (49) 
 Keep OTC medications or supple-
ments handy at all times 
 569 (52) a  374 (45) 
 Avoid stressful situations  350 (32) a  199 (24) 
 Always stay near a bathroom  350 (32) a  183 (22) 
 Carry wipes when you’re on the go  252 (23) a  133 (16) 
 Avoid drinking alcohol  219 (20) a  133 (16) 
 Put off or avoid intimacy with a partner  197 (18) a  116 (14) 
 Wear different clothes such as over-
sized, looser, or dark-colored items 
 186 (17)  116 (14) 
 Carry an extra set of clothing  142 (13) a  66 (8) 
 Avoid exercise  44 (4)  25 (3) 
 Other  55 (5) a  17 (2) 
 None of the above  44 (4)  83 (10) b 
 Current lifestyle adjustments, mean  3.7  2.9 
 IBS, irritable bowel syndrome; IBS-D, diarrhea-predominant irritable bowel 
syndrome; OTC, over the counter. 
 a P <0.05 vs. undiagnosed. 
 b P <0.05 vs. diagnosed. 
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 Limitations of this study include those inherent to any survey-
based design (e.g., potential for sampling and recall bias). Recall 
bias may play a role in reporting of symptom severity ( 22 ), and 
comorbid conditions could potentially infl uence recall of symp-
tom severity ( 22 ). Th e cross-sectional nature of the study clearly 
does not allow for the investigation of causal relationships, and 
the analyses do not allow one to entirely separate the infl uences 
of symptom severity and IBS diagnosis. Th is study also did 
not comprehensively assess for comorbid functional disorders 
or structural diagnoses; without access to the patient medical 
records, physician diagnoses of IBS could not be confi rmed. 
Nevertheless, this study employed measures that were both reli-
able and validated; the study also successfully highlights several 
important clinical distinctions between “real-world” samples 
of symptomatic individuals with or without an IBS diagnosis 
( 23 ). Although we only studied patients with IBS-D symptoms 
using Rome III criteria, we anticipate that similar fi ndings likely 
would be present in IBS patients with constipation and mixed 
bowel patterns, and largely would extrapolate to the new Rome 
IV criteria ( 3 ), although this needs to be studied.
 In conclusion, a substantial percentage of individuals meeting 
Rome III criteria for IBS-D have not been formally diagnosed with 
IBS. Individuals with undiagnosed IBS generally experience milder 
and less disruptive GI symptoms, experience fewer supportive 
symptoms of IBS (e.g., urgency, bloating), and report symptoms 
for fewer years than their counterparts diagnosed with IBS-D; 
all these factors may challenge the clinician’s ability to make a 
defi nitive IBS-D diagnosis, particularly in the primary care setting. 
Nevertheless, it is important that providers maintain an appro-
priate index of suspicion in diagnosing IBS, as clinical recogni-
tion of this condition may enhance patient insight into potential 
etiopathologic factors that trigger symptoms (i.e., diet, stress) and 
may facilitate physician implementation of more proven, evidence-
based treatment approaches.
respectively) ( 8 ). Although dietary modifi cation and antidiar-
rheals were tried at some point by approximately half to two-thirds 
of individuals with undiagnosed or diagnosed IBS-D, respectively, 
antibiotics, antispasmodics, and serotonin (5-hydroxytryptamine 
type 3) antagonists that have benefi cial eff ects in IBS-D ( 2,15 ) 
were tried in only a small subset of patients. Patients diagnosed 
with IBS were also signifi cantly more likely ( P <0.05) in this study 
to manage symptoms by engaging in lifestyle modifi cations for 
which there are data supporting their use, such as abstaining from 
problematic foods and avoidance of stressful situations ( 16,17 ). 
Minimizing the use of prescription medications, when possible, 
has been suggested for patients with IBS, as patient education 
and reassurance are considered key aspects of disease manage-
ment ( 18 ). Symptom severity clearly is an important factor infl u-
encing therapeutic interventions; a previous study demonstrated 
that patients with severe IBS had a greater mean number of phy-
sician visits compared with patients with mild or moderate IBS 
( 19 ). Results of this same study indicated that patients with severe 
IBS were receiving a greater mean number of medications com-
pared with patients with mild or moderate IBS (2.5 vs. 1.6 and 1.9, 
respectively) ( 19 ).
 Th e second reason why a formal IBS-D diagnosis is valuable is 
that patients with this distinction appeared to be better informed 
about IBS pathophysiology, reporting explanations for their symp-
toms that are more scientifi cally derived (e.g., diet, genetics, and 
intestinal microbiota) compared with undiagnosed individuals. 
Conversely, one-third of those without an IBS-D diagnosis reported 
that they had been provided no explanation by their healthcare 
provider for their GI symptoms. Once established, a diagnosis ena-
bles the symptomatic individual to seek out additional informa-
tional and support resources; such knowledge is central to patient 
empowerment strategies that have recently proven useful in the 
management of a variety of chronic pain conditions ( 20,21 ) and 
















































































































 Figure 3 .  Participant perceptions of irritable bowel syndrome (IBS) etiology. This ﬁ gure shows the percentage of individuals responding “deﬁ nitely a cause” 
to the question “To the best of your knowledge, which of the following do you believe are causing your IBS/stomach problems?”.  a P <0.05 vs. undiagnosed 
group.  b P <0.05 vs. diagnosed group.
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 Study Highlights
 WHAT IS CURRENT KNOWLEDGE 
 ✓  Symptoms of irritable bowel syndrome (IBS) adversely 
impact quality of life. 
 ✓  Many individuals with diarrhea-predominant IBS (IBS-D) 
remain undiagnosed. 
 ✓  Symptoms, healthcare utilization, and treatments in 
individuals with diagnosed or undiagnosed IBS-D are not 
well characterized. 
 WHAT IS NEW HERE 
 ✓  Severity of symptoms and impact on quality of life is 
greater in patients with diagnosed IBS compared with 
those who are undiagnosed. 
 ✓  One-third of individuals with undiagnosed IBS reported 
that they had been provided no explanation for their GI 
symptoms by their healthcare provider. 
 ✓  Nearly two-thirds of undiagnosed individuals had never 
considered that they might have IBS-D. 
 ✓  Only a small subset of individuals with IBS-D have been 
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